Literature DB >> 281559

Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D.

L J Wilkoff, E A Dulmadge.   

Abstract

Cultured P388 cells derived from leukemia P388 passaged in vivo in (C57BL X DBA/2)F1 mice were approximately one-tenth less sensitive to N-trifluoroacetyladriamycin-14-valerate (AD32) and cinerubin A, inasmuch as the concentrations of these agents had to be increased tenfold to produce a reduction in cell viability of the same order of magnitude as that produced by adriamycin, daunomycin, or actinomycin D. Cultured P388 cells derived from resistant cell populations developed in vivo retained their resistance to vincristine. These resistant cells exhibited cross-resistance to actinomycin D, adriamycin, daunomycin, and AD32, but cross-resistance to cinerubin A could not be detected. Data also showed that the vincristine-resistant cells were more sensitive to AD32 (2.8 x 10(-6) M) than to adriamycin (3.4 x 10(-6) M) during a 6-hour exposure of cells to agents.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 281559

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

1.  Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.

Authors:  I Pályi; J Bence; K Szikla; L Hullán
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.

Authors:  R Supino; M Mariani; E Prosperi; G Parmiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Spirogermanium--a novel antitumour agent expressing a lack of cross-resistance in vitro with a range of 'standard' antitumour drugs.

Authors:  B T Hill; R D Whelan
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  Cells resistant to cytotoxic drugs are recognized by monoclonal antibody.

Authors:  C J O'Hara; J Grover; G B Price
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

5.  Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol.

Authors:  D Fan; G Poste; C Seid; L E Earnest; T Bull; R K Clyne; I J Fidler
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.

Authors:  K Nooter; R Oostrum; R Jonker; H van Dekken; W Stokdijk; G van den Engh
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.

Authors:  A Ramu; M Fridkin; R Steinherz
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.

Authors:  L J Wilkoff; D A Dulmadge; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Long-term culture of epithelial cells from the normal rat colon.

Authors:  D P Chopra; K Y Yeh
Journal:  In Vitro       Date:  1981-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.